Therapixel, the developer of MammoScreen, an AI-based breast cancer screening software, announces that Mayo Clinic has procured licenses for the use of MammoScreen across its radiology departments. The software provides radiologists with AI-generated insights to support the interpretation of screening mammograms.
Health Technology Insights: FUJIFILM Diosynth and Regeneron Sign $3Billion 10-Year U.S. Deal
Therapixel previously participated in the MedTech Accelerator Program, a Mayo Clinic and Arizona State University Alliance for Health Care initiative designed to support early-stage health technology companies. Following internal evaluations, Mayo Clinic has licensed MammoScreen for use in its clinical workflow.
Health Technology Insights: Patient Experience University (PXU) launched by The Beryl Institute
MammoScreen is designed to assist radiologists by providing decision support in the interpretation of screening exams, with the goal of enhancing diagnostic efficiency and accuracy.
“This license agreement represents a meaningful step in making our AI tools accessible to more radiologists and patients,” said Matthieu Leclerc-Chalvet, CEO of Therapixel.
Health Technology Insights: Havas Reveals Inequities in HCP Training and Practices
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
